Oncolytics Biotech® Inc. Collaborators to Present Positive Phase 2 REOLYSIN Clinical Data in Pancreatic Cancer at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference |
 |
 |
| Tuesday, 15 November 2011 21:57 |
|
The poster, entitled “A Phase II Study of REOLYSIN® in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma”, authored by Mita et al, indicated that as of the date of submission of the poster that 12 patients were evaluable for response. All patients except one reported symptomatic improvement. Seven patients had stable disease (SD) for 12 weeks or longer, for a clinical benefit rate (complete response (CR) + partial response (PR) + SD) of 58%.This included two patients who had SD for 36 weeks or longer. An additional patient had an unconfirmed PR of less than six weeks. The treatment was well tolerated with manageable adverse events. This study is using a one sample, two-stage design. In the first stage, 17 patients were to be enrolled, and best response noted. If less than three responses (defined as CR or PR or SD for 12 weeks or more) were observed, the study would have concluded that the combination was inactive and been terminated. If three or more responses were observed among the 17 patents, the study would enroll an additional 16 patients for a total of 33 evaluable patients. As previously disclosed, this endpoint was met after six evaluable patients were enrolled. If at least eight responses are observed out of 33 patients, the study will conclude that the drug combination is active. This study will be updated if and when this endpoint is reached. “Pancreatic cancer typically offers a dismal prognosis, so it is highly encouraging to see the clinical benefit rate reported in this study. The median progression free survival for pancreatic patients on gemcitabine is nine weeks1, whilst the majority of the patients on this study had not progressed as of 12 weeks,” said Dr. Brad Thompson, President and CEO of Oncolytics. “We intend to continue testing REOLYSIN with various chemotherapeutic agents including gemcitabine and carboplatin/paclitaxel across multiple trials to further understand its potential in the treatment of pancreatic cancer.” 1Burris,H.A. et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J ClinOncol 15(6):2403-2413. BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
about 1 hour ago
Cancer Survivors Who Exercise Live Longer http://t.co/U4MhX04a
about 2 hours ago
Colon cancer screenings that don’t require laxatives are almost as effective as colonoscopies and may encourage more tests http://j.m…
about 2 hours ago
Testing a Drug That May Stop Alzheimer’s Before It Starts $RHHBY http://t.co/Wjgw15IS
about 3 hours ago
Two patients get eye stem cells transplanted to restore sight http://t.co/HHYZlFFT
about 3 hours ago
US Senate call to scrap drug patents: http://t.co/W1BOuxJp
about 3 hours ago
http://t.co/MAgh4Xke
about 3 hours ago
Eyeing the inflammasome http://t.co/89KnKhiM
about 3 hours ago
Vitamin D Levels May Reduce Risk of Macular Degeneration http://t.co/v6iFFOq2
Free Phone Trade Alerts
